Vepalimomab Explained

Vepalimomab is an experimental mouse monoclonal antibody intended for the treatment of inflammations. It blocks vascular adhesion protein 1.[1] Development of the drug was discontinued in 2002.[2]

Notes and References

  1. Vainio PJ, Kortekangas-Savolainen O, Mikkola JH, Jaakkola K, Kalimo K, Jalkanen S, Veromaa T . Safety of blocking vascular adhesion protein-1 in patients with contact dermatitis . Basic & Clinical Pharmacology & Toxicology . 96 . 6 . 429–35 . June 2005 . 15910406 . 10.1111/j.1742-7843.2005.pto_05.x . free .
  2. Web site: Vepalimomab . AdisInsight . Springer Nature Switzerland AG .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Vepalimomab".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.